Ovarian cancer is the most deadly malignant tumor of female reproductive tract, with a current incidence rate of 8.14/100,000 and mortality rate of 3.13/100,000 in China. Due to the lack of effective early diagnosis methods, 70% of patients are already at advanced stage when they are first diagnosed, and treatment is quite difficult. Therefore, early diagnosis and standardized treatment have become the most important issues in the diagnosis and treatment of ovarian cancer. As reported by Powell et al. at the Society of Gynecologic Oncologists (SGO) 2011 meeting, an SGO Quality and Outcomes Committee study based on the National Cancer Database and including 144,449 patients found that adherence to NCCN guidelines for treatment was associated with improved survival in advanced ovarian cancer, but even in countries with relatively high levels of ovarian cancer care such as the United States, advanced However, even in countries with relatively high levels of ovarian cancer care, such as the United States, the rate of standardized treatment for advanced ovarian cancer is only 43.2%. The situation in China is even more worrisome. The inaccurate staging of early-stage ovarian cancer without lymph node dissection or removal of only pelvic lymph nodes leads to incorrect prognosis estimation and treatment selection, and a considerable number of patients are either under-treated or over-treated; the low satisfaction rate of initial tumor cytoreductive surgery for advanced ovarian cancer results in more patients with chemotherapy resistance and poor prognosis; the treatment of recurrent ovarian cancer is even more confusing, and a considerable number of patients suitable for reoperation are deprived of surgical treatment. The treatment of recurrent ovarian cancer is even more confusing, and a considerable number of patients who are suitable for surgery again lose the best time for surgery, and chemotherapy seriously affects patients’ quality of life, and even death due to chemotherapy side effects happens from time to time. All these show that the standardized treatment of ovarian cancer needs to be strengthened.